Home

Empfänger Analytiker Werdegang zur rose group ag investor relations genetisch schnappen überspringen

Corporate Governance
Corporate Governance

Sustainable and profitable: Evonik keeps growing - Evonik Industries
Sustainable and profitable: Evonik keeps growing - Evonik Industries

Corporate Governance - Annual Report 2020 | Zur Rose Group AG
Corporate Governance - Annual Report 2020 | Zur Rose Group AG

Zur Rose Group – Marke
Zur Rose Group – Marke

Olaf Heinrich, Head Germany, verlässt die Zur Rose-Gruppe; sein Nachfolger  wird Walter Hess, Head Switzerland
Olaf Heinrich, Head Germany, verlässt die Zur Rose-Gruppe; sein Nachfolger wird Walter Hess, Head Switzerland

Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term  growth opportunity ? | value and opportunity
Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term growth opportunity ? | value and opportunity

ZUR ROSE GROUP AG : Shareholders Board Members Managers and Company Profile  | CH0042615283 | MarketScreener
ZUR ROSE GROUP AG : Shareholders Board Members Managers and Company Profile | CH0042615283 | MarketScreener

Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St
Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St

Zur Rose Group AG - Crunchbase Company Profile & Funding
Zur Rose Group AG - Crunchbase Company Profile & Funding

Zur Rose Aerzte AG Share Price CHF5.75
Zur Rose Aerzte AG Share Price CHF5.75

Olaf Heinrich, Head Germany, is leaving the Zur Rose Group; his successor  will be Walter Hess, Head Switzerland
Olaf Heinrich, Head Germany, is leaving the Zur Rose Group; his successor will be Walter Hess, Head Switzerland

Christoph Herrmann - Director Investor Relations - Zur Rose Group AG | XING
Christoph Herrmann - Director Investor Relations - Zur Rose Group AG | XING

Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St
Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St

Zur Rose Group - Pharmaceuticals - Overview, Competitors, and Employees |  Apollo.io
Zur Rose Group - Pharmaceuticals - Overview, Competitors, and Employees | Apollo.io

Financials - Annual Report 2020 | Zur Rose Group AG
Financials - Annual Report 2020 | Zur Rose Group AG

Christoph Herrmann – Head of Investor Relations – Zur Rose Group | LinkedIn
Christoph Herrmann – Head of Investor Relations – Zur Rose Group | LinkedIn

The NAGA Group AG: Products, Stock, News
The NAGA Group AG: Products, Stock, News

Investor Relations | Schindler Group
Investor Relations | Schindler Group

Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term  growth opportunity ? | value and opportunity
Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term growth opportunity ? | value and opportunity

Financial News | Beiersdorf
Financial News | Beiersdorf

ZUR ROSE GROUP AG : Shareholders Board Members Managers and Company Profile  | CH0042615283 | MarketScreener
ZUR ROSE GROUP AG : Shareholders Board Members Managers and Company Profile | CH0042615283 | MarketScreener

FY 2021 IFRS RESULTS - EuroChem Group
FY 2021 IFRS RESULTS - EuroChem Group

Acquisitions by Zur Rose Group | Tracxn
Acquisitions by Zur Rose Group | Tracxn